Key Takeaway: IgDesign™ represents a significant advancement in antibody design, being the first experimentally validated inverse folding model. It demonstrates the capability to create antibody binders for various therapeutic antigens with high success rates, often surpassing the affinities of existing reference antibodies. This innovation is poised to enhance drug development and therapeutic design processes.
Price reaction · baseline $5.01 (2024-05-01T13:39:00.000Z) · hit during market hours · clean, no other ABSI news in the window
day 0 close · peak
+3.6%
Market Sentiment Analysis
POSITIVE FACTORS
IgDesign™ is the first experimentally validated antibody inverse folding model.
It can design antibody binders with high success rates.
IgDesign™ shows improved affinities over clinically validated reference antibodies.
It has applications in both de novo antibody design and lead optimization.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Cash runway
~12 mo
Medium dilution risk
Lead asset
ABS-201 Single Dose
Phase 1 · Androgenetic Alopecia (AGA)
Full Press Release Details
IgDesign™: Antibody inverse folding with in vitro validation
IgDesign™ is the first experimentally validated antibody inverse folding model. It can design antibody binders to multiple therapeutic antigens with high success rates and, in some cases, improved affinities over clinically validated reference antibodies. Antibody inverse folding has applications to both de novo antibody design and lead optimization, making IgDesign™ a valuable tool for drug development and enabling therapeutic design.
Frequently Asked Questions
What is IgDesign™?
IgDesign™ is the first experimentally validated antibody inverse folding model.
What are the applications of IgDesign™?
IgDesign™ is used for de novo antibody design and lead optimization.
How does IgDesign™ improve antibody design?
It designs antibody binders with high success rates and improved affinities.
What is antibody inverse folding?
Antibody inverse folding is a method to design antibody binders for therapeutic antigens.